These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38245663)

  • 1. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system.
    Zhao Y; Jiang H; Xue L; Zhou M; Zhao X; Liu F; Jiang S; Huang J; Meng L
    Int J Clin Pharm; 2024 Apr; 46(2):480-487. PubMed ID: 38245663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.
    Li Y; Zhang N; Jiang T; Gan L; Su H; Wu Y; Yang X; Xiang G; Ni R; Xu J; Li C; Liu Y
    Pediatr Neurol; 2024 Sep; 158():71-78. PubMed ID: 38981277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
    Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
    Caldito NG; Shirani A; Salter A; Stuve O
    Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.
    Hu JL; Wu JY; Xu S; Qian SY; Jiang C; Zheng GQ
    J Headache Pain; 2024 Oct; 25(1):169. PubMed ID: 39375581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.
    Cui S; Li L; Liu W; Zhao B; Zhong X
    Braz J Med Biol Res; 2024; 57():e13392. PubMed ID: 39082578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.
    Park S; Choi SH; Song YK; Kwon JW
    JMIR Public Health Surveill; 2022 Jan; 8(1):e33311. PubMed ID: 34982723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.
    Du Y; Zhu J; Guo Z; Wang Z; Wang Y; Hu M; Zhang L; Yang Y; Wang J; Huang Y; Huang P; Chen M; Chen B; Yang C
    Expert Rev Clin Pharmacol; 2024; 17(2):189-201. PubMed ID: 38269492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System.
    Zhao Y; Zhang Y; Yang L; Zhang K; Li S
    Ann Pharmacother; 2024 Nov; 58(11):1105-1116. PubMed ID: 38407147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.